Brainstorm Cell Therapeutics 미래 성장

Future 기준 확인 0/6

Brainstorm Cell Therapeutics은 연간 수입과 매출이 각각 15.9%와 91.5% 증가할 것으로 예상되고 EPS는 연간 26.4%만큼 증가할 것으로 예상됩니다.

주요 정보

15.9%

수익 성장률

26.4%

EPS 성장률

Biotechs 수익 성장	42.4%
매출 성장률	91.5%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	12 Nov 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

DB:GHD - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	N/A	-26	-44	N/A	3
12/31/2025	N/A	-25	-13	-12	3
12/31/2024	N/A	-14	-14	-14	3
9/30/2024	N/A	-14	-11	-11	N/A
6/30/2024	N/A	-13	-14	-14	N/A
3/31/2024	N/A	-16	-20	-20	N/A
12/31/2023	N/A	-17	-20	-20	N/A
9/30/2023	N/A	-17	-22	-22	N/A
6/30/2023	N/A	-22	-20	-20	N/A
3/31/2023	N/A	-24	-20	-20	N/A
12/31/2022	N/A	-24	-19	-19	N/A
9/30/2022	N/A	-25	-20	-20	N/A
6/30/2022	N/A	-24	-22	-22	N/A
3/31/2022	N/A	-23	-21	-21	N/A
12/31/2021	N/A	-24	-27	-26	N/A
9/30/2021	N/A	-30	-29	-28	N/A
6/30/2021	N/A	-29	-29	-29	N/A
3/31/2021	N/A	-30	-30	-29	N/A
12/31/2020	N/A	-32	-36	-35	N/A
9/30/2020	N/A	-28	-31	-31	N/A
6/30/2020	N/A	-29	-28	-28	N/A
3/31/2020	N/A	-26	-26	-25	N/A
12/31/2019	N/A	-23	-12	-11	N/A
9/30/2019	N/A	-21	-12	-12	N/A
6/30/2019	N/A	-18	-15	-15	N/A
3/31/2019	N/A	-17	-11	-11	N/A
12/31/2018	N/A	-14	-13	-12	N/A
9/30/2018	N/A	-8	-12	-12	N/A
6/30/2018	N/A	-8	N/A	-1	N/A
3/31/2018	N/A	-5	N/A	-3	N/A
12/31/2017	N/A	-5	N/A	-2	N/A
9/30/2017	N/A	-6	N/A	-1	N/A
6/30/2017	N/A	-5	N/A	-5	N/A
3/31/2017	N/A	-5	N/A	-5	N/A
12/31/2016	N/A	-5	N/A	-6	N/A
9/30/2016	N/A	-6	N/A	-6	N/A
6/30/2016	N/A	-7	N/A	-8	N/A
3/31/2016	N/A	-8	N/A	-8	N/A
12/31/2015	N/A	-8	N/A	-7	N/A
9/30/2015	N/A	-10	N/A	-8	N/A
6/30/2015	N/A	-10	N/A	-7	N/A
3/31/2015	N/A	-9	N/A	-6	N/A
12/31/2014	N/A	-9	N/A	-4	N/A
9/30/2014	N/A	-8	N/A	-4	N/A
6/30/2014	N/A	-6	N/A	-4	N/A
3/31/2014	N/A	-6	N/A	-4	N/A

애널리스트 미래 성장 예측

수입 대 저축률: GHD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: GHD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: GHD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: GHD 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: GHD 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: GHD 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Brainstorm Cell Therapeutics 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Forecast to breakeven in 2025

Forecast to breakeven in 2025

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Brainstorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brainstorm Cell Therapeutics Implements 1-for-15 Reverse Stock Split to Meet Nasdaq's Minimum Bid Price Requirement

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Sep 16, 2024

Brainstorm Cell Therapeutics Receives Deficiency Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Pursuant to Nasdaq Listing Rule 5550(b)(2)

Brainstorm Cell Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4 million.

Brainstorm Cell Therapeutics Inc. Reaches Alignment with Fda on Cmc Aspects of Phase 3B Nurown®? Clinical Trial

New major risk - Revenue and earnings growth

Brainstorm Cell Therapeutics Announces Appointment of Haro Hartounian as EVP and COO

Brainstorm Cell Therapeutics Inc. Announces Non-Compliance Update

Brainstorm Cell Therapeutics Receives Staff Determination Letter from Nasdaq Regarding it Not Regains Compliance with the Minimum Bid Price Requirement by April 29, 2024 and Submits a Hearing Request to the Nasdaq Hearings Panel to Appeal the Staff’s Determination

Brainstorm Cell Therapeutics Inc. Announces Management Changes

BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule

BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS

New major risk - Shareholder dilution

BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn in ALS

Brainstorm Cell Therapeutics Inc. Announces Executive Changes

BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS

Brainstorm Cell Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance Market Value of Listed Securities Requirement for Continued Listing on The Nasdaq Capital Market

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Dec 18, 2023

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

Brainstorm Cell Therapeutics Receives Non-Compliance Notice from Nasdaq

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc

BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn for the Treatment of ALS

New minor risk - Profitability

Brainstorm Cell Therapeutics Inc. to Report Q2, 2023 Results on Aug 14, 2023

BrainStorm Cell Therapeutics Inc. Appoints Bob Dagher as Executive Vice President and Chief Development Officer

Brainstorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair

New minor risk - Market cap size

Forecast to breakeven in 2025

Brainstorm Cell Therapeutics Inc Announces Resignation of David Setboun as Executive Vice President and Chief Operating Officer

Forecast to breakeven in 2025

No longer forecast to breakeven

BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer

Brainstorm Cell Therapeutics Inc. Announces Type A Meeting with FDA Granted for NurOwn®

Brainstorm Cell Therapeutics Inc., Annual General Meeting, Jan 10, 2023

BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration

Brainstorm Cell Therapeutics Seeks FDA Approval of Mesenchymal Stem Cell Therapy Called NurOwn for the Treatment of ALS

Brainstorm Cell Therapeutics Inc. Receives Refusal to File Letter from FA for Its New Biologics License Application for Nurown for the Treatment of Als

BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium

Brainstorm Cell Therapeutics Inc. Announces Peer Reviewed Publication of Results from the Nurown Phase 2 Progressive MS Trial in Multiple Sclerosis Journal

Brainstorm Cell Therapeutics Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for NurOwn for the Treatment of Amyotrophic Lateral Sclerosis

Brainstorm Cell Therapeutics Inc. Appoints Antal Pearl-Lendner as Chief Legal Counsel

BrainStorm Cell Therapeutics Inc. Announces Presentation of Nurown® Exosome Preclinical Data At ISCT 2022 San Francisco Meeting

U.S. Food and Drug Administration Authorizes Further Brainstorm Cell Therapeutics Inc.'s Nurown Dosing Under Expanded Access Program

Brainstorm Cell Therapeutics Announces Peer Reviewed Publication of Nurown's® Phase 3 Study for Als in Muscle and Nerve

BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium

No longer forecast to breakeven

Brainstorm Cell Therapeutics Inc.(NasdaqCM:BCLI) dropped from Russell 3000 Growth Index

New 90-day low: €3.28

Brainstorm Cell Therapeutics Inc. Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program

Brainstorm Cell Therapeutics Inc. Announces Feedback from FDA Type-C Meeting on Future NurOwn® Manufacturing Plan

Brainstorm Cell Therapeutics Inc. to Report Q4, 2020 Results on Feb 04, 2021

BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS

Brainstorm Cell Therapeutics Inc. Announces Completion of All Dosing in NurOwn® Phase 2 MS Study

BrainStorm Announces NurOwn® Expanded Access Program

New 90-day low: €3.42

BrainStorm Cell Therapeutics Inc. Announces Topline Results from NurOwn® Phase 3 ALS Study

New 90-day high: €14.80

Brainstorm Cell Therapeutics Inc. Appoints William K. White as Senior Vice President, Head of Market Access & Pricing

Brainstorm Cell Therapeutics Inc. to Report Q2, 2020 Results on Aug 03, 2020

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견